Cooperating transcription factors mediate the function of estrogen receptor

Chromosoma

Volumn 122, Issue 1-2, 2013, Pages 1-12

  Fiorito, Elisa ^a   Katika, Madhumohan R ^a   Hurtado, Antoni ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR GATA; TRANSCRIPTION FACTOR HOMEOBOX; TRANSCRIPTION FACTOR PAX2; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR PITX1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

BREAST; BREAST CANCER; CELL DIFFERENTIATION; CELL DIVISION; CHROMATIN; CYTOPLASM; DRUG RESPONSE; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; OVARY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; UTERUS;

BREAST NEOPLASMS; CELL DIVISION; CHROMATIN; DNA-BINDING PROTEINS; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 84876475178     PISSN: 00095915     EISSN: 14320886     Source Type: Journal    
DOI: 10.1007/s00412-012-0392-7     Document Type: Review

References (124)

1. Abe Y, Ijichi N et al (2012) Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells. Cancer Sci 103(4):806-812
2. Ademuyiwa FO, Thorat MA et al (2010) Expression of forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low oncotype DX 21-gene recurrence scores. Mod Pathol 23(2):270-275
3. Albergaria A, Paredes J et al (2009) Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Res 11(3):R40
4. Ali SA, Zaidi SK et al (2010) Transcriptional corepressor TLE1 functions with Runx2 in epigenetic repression of ribosomal RNA genes. Proc Natl Acad Sci U S A 107(9):4165-4169
5. Anzick SL, Kononen J et al (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277(5328):965-968
6. Arnold SF, Obourn JD et al (1994) Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 8(9):1208-1214
7. Asselin-Labat ML, Sutherland KD et al (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9(2):201-209
8. Beauchemin D, Lacombe C et al (2011) PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype. Mol Cancer 10:148
9. Benz CC, Scott GK et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85-95
10. Bernardo GM, Bebek G et al (2012) FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene. doi: 10.1038/onc.2012.62
11. Berns K, Horlings HM et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer cell 12(4):395-402
12. Bossard P, Zaret KS (1998) GATA transcription factors as potentiators of gut endoderm differentiation. Development 125(24):4909-4917
13. Carroll JS, Liu XS et al (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122(1):33-43
14. Carroll JS, Meyer CA et al (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38(11):1289-1297
15. Carvalho LR, Brinkmeier ML et al (2010) Corepressors TLE1 and TLE3 interact with HESX1 and PROP1. Mol Endocrinol 24(4):754-765
16. Chen D, Pace PE et al (1999a) Phosphorylation of human estrogen receptor alpha by protein kinase A regulates dimerization. Mol Cell Biol 19(2):1002-1015
17. Chen D, Washbrook E et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921-4931
18. Chen H, Lin RJ et al (1999b) Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98(5):675-686
19. Cheng AS, Jin VX et al (2006) Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 21(3):393-404
20. Cirillo LA, McPherson CE et al (1998) Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J 17(1):244-254
21. Clarke CL, Graham JD (2012) Non-overlapping progesterone receptor cistromes contribute to cell-specific transcriptional outcomes. PLoS One 7(4):e35859
22. Clauss IM, Chu M et al (1996) The basic domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE-like sequences containing an ACGT core. Nucleic Acids Res 24(10):1855-1864
23. Cowper-Sal Lari R, Zhang X et al (2012) Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet 44(11):1191-1198
24. Curtis C, Shah SP et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346-352
25. Dahl E, Koseki H et al (1997) Pax genes and organogenesis. Bioessays 19(9):755-765
26. Daniels DL, Weis WI (2005) Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 12(4):364-371
27. Darro F, Cahen P et al (1998) Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 51(1):39-55
28. Dasen JS, Barbera JP et al (2001) Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes Dev 15(23):3193-3207
29. Davies MP, Barraclough DL et al (2008) Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer. Int J Cancer 123(1):85-88
30. Dawson MI, Chao WR et al (1995) Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 55(19):4446-4451
31. Ding L, Yan J et al (2003) Ligand-independent activation of estrogen receptor alpha by XBP-1. Nucleic Acids Res 31(18):5266-5274
32. Dowsett M (2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Cancer 8(3):191-195
33. Drury SC, Detre S et al (2011) Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 18(5):565-577
34. Eeckhoute J, Carroll JS et al (2006) A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 20(18):2513-2526
35. Eeckhoute J, Keeton EK et al (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67(13):6477-6483
36. Fagan DH, Uselman RR et al (2012) Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment. Cancer Res 72(13):3372-3380
37. Fisher B, Costantino JP et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371-1388
38. Frasor J, Chang EC et al (2006) Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 66(14):7334-7340
39. Fullwood MJ, Liu MH et al (2009) An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 462(7269):58-64
40. Gerhardt J, Montani M et al (2012) FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am J Pathol 180(2):848-861
41. Giguere V, Ong ES et al (1987) Identification of a receptor for the morphogen retinoic acid. Nature 330(6149):624-629
42. Gilfillan S, Fiorito E et al (2012) Functional genomic methods to study estrogen receptor activity. J Mammary Gland Biol Neoplasia 17(2):147-153
43. Gomez BP, Riggins RB et al (2007) Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB J 21(14):4013-4027
44. Gray J, Druker B (2012) Genomics: the breast cancer landscape. Nature 486(7403):328-329
45. Habashy HO, Powe DG et al (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44(11):1541-1551
46. Harvey JM, Clark GM et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474-1481
47. Higgins MJ, Stearns V (2009) Understanding resistance to tamoxifen in hormone receptor-positive breast cancer. Clin Chem 55(8):1453-1455
48. Ho IC, Pai SY (2007) GATA-3 - not just for Th2 cells anymore. Cell Mol Immunol 4(1):15-29
49. Holmes KA, Hurtado A et al (2012) Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc Natl Acad Sci U S A 109(8):2748-2753
50. Houtman R, de Leeuw R et al (2012) Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol Cancer Ther 11(4):805-816
51. Hua S, Kittler R et al (2009) Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137(7):1259-1271
52. Hurtado A, Holmes KA et al (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456(7222):663-666
53. Hurtado A, Holmes KA et al (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43(1):27-33
54. Jennings BH, Pickles LM et al (2006) Molecular recognition of transcriptional repressor motifs by the WD domain of the Groucho/TLE corepressor. Mol Cell 22(5):645-655
55. Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980-1989
56. Jordan VC, Gapstur S et al (2001) Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93(19):1449-1457
57. Kaestner KH, Knochel W et al (2000) Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 14(2):142-146
58. Kato S, Endoh H et al (1995) Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241):1491-1494
59. Katzenellenbogen BS, Frasor J (2004) Therapeutic targeting in the estrogen receptor hormonal pathway. Semin Oncol 31(1 Suppl 3):28-38
60. Kok M, Zwart W. et al (2011) PKA-induced phosphorylation of ERalpha at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 125(1):1-12
61. Kong SL, Li G et al (2011) Cellular reprogramming by the conjoint action of ERalpha, FOXA1, and GATA3 to a ligand-inducible growth state. Mol Syst Biol 7:526
62. Kouros-Mehr H, Kim JW et al (2008) GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20(2):164-170
63. Krum SA, Miranda-Carboni GA et al (2008) Unique ERalpha cistromes control cell type-specific gene regulation. Mol Endocrinol 22(11):2393-2406
64. Kushner PJ, Agard DA et al (2000) Estrogen receptor pathways to AP-1. J Steroid Biochem Mol Biol 74(5):311-317
65. Laganiere J, Deblois G et al (2005a) Functional genomics identifies a mechanism for estrogen activation of the retinoic acid receptor alpha1 gene in breast cancer cells. Mol Endocrinol 19(6):1584-1592
66. Laganiere J, Deblois G et al (2005b) From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc Natl Acad Sci U S A 102(33):11651-11656
67. Leung E, Kannan N et al (2010) MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivity. Cancer Biol Ther 9(9):717-724
68. Levanon D, Goldstein RE et al (1998) Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A 95(20):11590-11595
69. Li C, Liang YY, et al (2008) Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/AIB1 coactivator function and turnover. Mol Cell 31(6):835-849
70. Likhite VS, Stossi F et al (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20(12):3120-3132
71. Lin CY, Vega VB et al (2007) Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 3(6):e87
72. Liu JK, DiPersio CM et al (1991) Extracellular signals that regulate liver transcription factors during hepatic differentiation in vitro. Mol Cell Biol 11(2):773-784
73. Liu Q, Li JG et al (2009) Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas. Chin Med J (Engl) 122(22):2763-2769
74. Lupien M, Eeckhoute J et al (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132(6):958-970
75. Magnani L, Ballantyne EB et al (2011) PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet 7(11):e1002368
76. Malik S, Jiang S et al (2010) Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol 30(2):399-412
77. Mansouri A, Hallonet M et al (1996) Pax genes and their roles in cell differentiation and development. Curr Opin Cell Biol 8(6):851-857
78. Miller TW, Balko JM et al (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 29(33):4452-4461
79. Miranda-Carboni GA, Guemes M et al (2011) GATA4 regulates estrogen receptor-alpha-mediated osteoblast transcription. Mol Endocrinol 25(7):1126-1136
80. Moens CB, Selleri L (2006) Hox cofactors in vertebrate development. Dev Biol 291(2):193-206
81. Monaghan AP, Kaestner KH et al (1993) Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 alpha, beta and gamma genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. Development 119(3):567-578
82. Muratovska A, Zhou C et al (2003) Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22(39):7989-7997
83. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643
84. Naderi A, Meyer M et al (2012) Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer. Neoplasia 14(4):283-296
85. Nakshatri H, Badve S (2009) FOXA1 in breast cancer. Expert Rev Mol Med 11:e8
86. Ni M, Chen Y et al (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1):119-131
87. Nicholson RI, Hutcheson IR et al (2002) Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann N Y Acad Sci 963:104-115
88. Onate SA, Tsai SY et al (1995) Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270(5240):1354-1357
89. Osborne CK, Bardou V et al (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95(5):353-361
90. Osborne CK, Schiff R (2003) Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 12(6):362-367
91. Paroni G, Fratelli M et al (2012) Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 31(29):3431-3443
92. Perou CM, Sorlie T et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
93. Persson I (2000) Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74(5):357-364
94. Porter W, Saville B et al (1997) Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 11(11):1569-1580
95. Prat A, Baselga J (2008) The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 5(9):531-542
96. Rayala SK, Talukder AH et al (2006) P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 66(3):1694-1701
97. Robinson JL, Macarthur S et al (2011) Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J 30(15):3019-3027
98. Ross-Innes CS, Stark R et al (2010) Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev 24(2):171-182
99. Ross-Innes CS, Stark R et al (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481(7381):389-393
100. Sahu B, Laakso M et al (2011) Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J 30(19):3962-3976
101. Schiff R, Massarweh S et al (2003) Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 9(1 Pt 2):447S-454S
102. Scriven P, Coulson S et al (2009) Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer 101(10):1692-1698
103. Sekiya T, Zaret KS (2007) Repression by Groucho/TLE/Grg proteins: genomic site recruitment generates compacted chromatin in vitro and impairs activator binding in vivo. Mol Cell 28(2):291-303
104. Silberstein GB, Dressler GR et al (2002) Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growth. Oncogene 21(7):1009-1016
105. Sorlie T, Perou CM et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98(19):10869-10874
106. Sorlie T, Tibshirani R et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100(14):8418-8423
107. Stender JD, Kim K et al (2010) Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol 30(16):3943-3955
108. Stifani S, Blaumueller CM et al (1992) Human homologs of a Drosophila enhancer of split gene product define a novel family of nuclear proteins. Nat Genet 2(4):343
109. Stossi F, Madak-Erdogan Z et al (2009) Estrogen receptor alpha represses transcription of early target genes via p300 and CtBP1. Mol Cell Biol 29(7):1749-1759
110. Su Q, Hu S et al (2008) Role of AIB1 for tamoxifen resistance in estrogen receptor-positive breast cancer cells. Oncology 75(3-4):159-168
111. Tan SK, Lin ZH et al (2011) AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J 30(13):2569-2581
112. Thomas RS, Sarwar N et al (2008) Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-alpha activity. J Mol Endocrinol 40(4):173-184
113. Toma S, Isnardi L et al (1998) Induction of apoptosis in MCF-7 breast carcinoma cell line by RAR and RXR selective retinoids. Anticancer Res 18(2A):935-942
114. Torchia J, Rose DW et al (1997) The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387(6634):677-684
115. Tozlu S, Girault I et al (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13(4):1109-1120
116. Wang D, Garcia-Bassets I et al (2011) Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 474(7351):390-394
117. Wang DY, Fulthorpe R et al (2004) Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 18(2):402-411
118. Williams CC, Basu A et al (2009) Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2. BMC Biochem 10:36
119. Wilson BJ, Giguere V (2008) Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 7:49
120. Wolff AC, Hammond ME et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(1):118-145
121. Wu H, Chen Y et al (2005) Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438(7070):981-987
122. Zeleniuch-Jacquotte A, Akhmedkhanov A et al (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84(7):975-981
123. Zhang Y, Liu T et al (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9(9):R137
124. Zhou Y, Eppenberger-Castori S et al (2005) Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37(5):1130-1144